High-dose AAV gene therapy deaths

  title={High-dose AAV gene therapy deaths},
  journal={Nature Biotechnology},
  pages={910 - 910}
  • Published 2020
  • Medicine
  • Nature Biotechnology

Topics from this paper

AAV8 locoregional delivery induces long-term expression of an immunogenic transgene in macaques despite persisting local inflammation
Results suggest that locoregional intravenous perfusion vector delivery promotes persisting transgene expression by induction of Treg cells in situ and might be a safe alternative to IM route to target large muscle territories for the expression of secreted therapeutic factors. Expand
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates
AAVCOVID-1, an adeno-associated viral (AAV), Spike gene-based vaccine candidate demonstrates potent immunogenicity in mouse and nonhuman primates following a single injection and confers complete protection from SARS-CoV-2 challenge in macaques. Expand
Base editing repairs an SGCA mutation in human primary muscle stem cells
The first evidence that autologous gene repaired human muscle stem cells can be harnessed for cell replacement therapies of muscular dystrophies is provided. Expand
CRISPR Gene-Editing Models Geared Toward Therapy for Hereditary and Developmental Neurological Disorders
How CRISPR can be used to generate research models to examine the effects of genetic variation and caffeine therapy on the developing brain and how it may be morphed into safe and effective therapy for HNDs and other brain disorders is discussed. Expand
Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?
The results demonstrate that, it may be possible to treat human KD patients with high dose AAVrh10 without blood stem cell transplantation which would eliminate the side effects of HSCT. Expand
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
As a “beneficial alliance” beyond Cas9-immunity, antigen-specific Treg cells may serve as a living and targeted immunosuppressant to increase safety and efficacy of gene therapy. Expand
Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models.
A state-of-the-art overview of current progress and limitations related to AAV mediated delivery of protein therapeutic genes, along with the perspective on the steps that need to be taken to improve clinical translation of this therapeutic modality is provided. Expand
Detect and destroy: CRISPR-based technologies for the response against viruses
This review summarizes how CRISPR-Cas systems—in particular the recently discovered DNA-targeting Cas12 and RNA- targeting Cas13, both possessing a unique trans-cleavage activity—are being harnessed for viral diagnostics and therapies. Expand
Engineering Viral Vectors for Acoustically Targeted Gene Delivery
High throughput in vivo selection is used to engineer new AAV vectors specifically designed for local neuronal transduction at the site of FUS-BBBO, boosting ultrasound-targeted gene delivery and neuronal tropism while reducing peripheral transduction, providing a more than ten-fold improvement in targeting specificity. Expand